Parkinson’s Disease Drug Therapies in the... - Cure Parkinson's

Cure Parkinson's

26,582 members27,897 posts

Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2020

Farooqji profile image
12 Replies

145 trials are registered and ongoing clinical trials for therapeutics targeting PD, of which 51 were Phase 1 (35% of the total number of trials), 66 were Phase 2 (46% ), and 28 were Phase 3 (19% ). There were 57 trials (39% ) focused on long-term disease modifying therapies, with the remaining 88 trials (61% ) focused on therapies for symptomatic relief. A total of 50 (34% ) trials were testing

content.iospress.com/articl...

Written by
Farooqji profile image
Farooqji
To view profiles and participate in discussions please or .
Read more about...
12 Replies
MissRita profile image
MissRita

Does anyone know how you get on board for a trial? I would love to be a guinea pig for the stuff but I just don’t know where to start. TIA!

Farooqji profile image
Farooqji in reply toMissRita

Go to clinicaltrials.gov, Search for the required trial and contact them as per the contract information provided

MissRita profile image
MissRita in reply toFarooqji

Thx!

WinnieThePoo profile image
WinnieThePoo in reply toMissRita

Michael J Fox foundation also have a trial finder site

michaeljfox.org/trial-finder

MissRita profile image
MissRita in reply toWinnieThePoo

Thx!

redhawk1 profile image
redhawk1

Stay tuned for study results of Phase 1 Denali DNL 151. If I were to get involved with another trial I would certainly consider the Denali Therapeutics Phase 2 DNL151 trial scheduled to begin sometime this year. Also, get a genetic test to determine specific genes that may be responsible for your disease inception.

Farooqji profile image
Farooqji in reply toredhawk1

Were you involved in Phase1? How was it

redhawk1 profile image
redhawk1 in reply toFarooqji

No. I am in Roche Prothena 2b study. But, trial center I attend is also sponsoring the Denali DNL151 phase 1 study. I always try to obtain snippets of information about other studies when I am there. The 5 cohorts taking part in the phase 1 Denali study all had “positive” reactions to the DNL151 medication. Had not heard such an endorsement about any other PD drug in my three years there as trial givers are hesitant to disclose any thoughts . . ., as they should be. Just saying . . .

Farooqji profile image
Farooqji in reply toredhawk1

How is PRX002 going. Any improvements reported by the participants?

redhawk1 profile image
redhawk1 in reply toFarooqji

Diagnosed March/2017 and in year 3 of study. Currently not taking any PD meds. Symptoms have progressed none the less . . . all be it slowly. Roche phase 2b apparently to continue up to 5 years.

MissRita profile image
MissRita in reply toredhawk1

I have been looking to get genetically tested but I’m not sure where or how to do it. Suggestions?

John_morris71 profile image
John_morris71

Anavex will soon be starting phase2/3 trial for PD using their drug A 2-73 which is a Sigma 1 Receptor. They had good results for PDD (Parkinson's Disease Dementia) and more details will soon be published in a peer review.

Not what you're looking for?

You may also like...

MRI-Focused Ultrasound Undergoing Phase 3 Clinical Trial for Parkinson’s Treatment

New technology that uses MRI-guided focused ultrasound to target areas of the brain affected by...
Farooqji profile image

UCB Announces Global Partnership to Bring Disease-Modifying Therapies to People Living with Parkinson’s Disease

UCB to partner with Novartis on development of UCB0599 with an opt-in to develop UCB7853, two...

Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson’s Disease

Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson’s...

Clinical Trial Highlights – an update on previously reviewed trials (Phase 3 in focus)

https://content.iospress.com/articles/journal-of-parkinsons-disease/jpd229001...

Hot off the press. Randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease.

Open access Published: 28 November 2023 Abstract Nicotinamide adenine dinucleotide (NAD)...